Literature DB >> 2779527

Ceftriaxone binding to human serum albumin: competition with bilirubin.

R Brodersen1, A Robertson.   

Abstract

Ceftriaxone, a cephalosporin, is bound reversibly to defatted human serum albumin from adults, with a first stoichiometric binding constant of 60,000 M-1, as found by equilibrium dialysis at pH 7.4, 37 degrees. A second molecule is weakly bound, with a binding constant of 500 M-1. Possible cobinding with bilirubin was studied by the peroxidase method and by equilibrium dialysis with and without added bilirubin. Results indicated competitive binding; formation of an albumin complex containing both bilirubin and ceftriaxone could not be demonstrated. Light absorption spectra of bilirubin-albumin showed little change on addition of ceftriaxone, in agreement with the competitive biding mechanism. Binding to serum albumin from newborn infants is weaker than to the protein from adults, with the first binding constant being about 36,000 M-1. Cobinding of ceftriaxone and bilirubin to albumin from newborn infants is likewise competitive. It is concluded that ceftriaxone is a strong bilirubin displacer with a potential of inducing bilirubin encephalopathy in predisposed newborns.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2779527

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Interaction of bilirubin with sealed and human serum albumin-entrapped sealed membranes.

Authors:  Huma Rashid; Mohammad Mushahid Khan; Saad Tayyab
Journal:  Mol Cell Biochem       Date:  2005-09       Impact factor: 3.396

2.  Protein binding predictions in infants.

Authors:  Patrick J McNamara; Jane Alcorn
Journal:  AAPS PharmSci       Date:  2002

Review 3.  Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature.

Authors:  Patrick C Donnelly; Rebecca M Sutich; Ryan Easton; Oluwatunmise A Adejumo; Todd A Lee; Latania K Logan
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

4.  Synthesis, Spectroscopic Studies for Five New Mg (II), Fe (III), Cu (II), Zn (II) and Se (IV) Ceftriaxone Antibiotic Drug Complexes and Their Possible Hepatoprotective and Antioxidant Capacities.

Authors:  Samy M El-Megharbel; Safa H Qahl; Fatima S Alaryani; Reham Z Hamza
Journal:  Antibiotics (Basel)       Date:  2022-04-20

5.  Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study.

Authors:  E Martin; S Fanconi; P Kälin; C Zwingelstein; C Crevoisier; W Ruch; R Brodersen
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

Review 6.  Adverse effects of newer cephalosporins. An update.

Authors:  J W Thompson; R F Jacobs
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 7.  Efficacy and safety of cefotaxime in the management of pediatric infections.

Authors:  R F Jacobs
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 8.  Recent advances in the ontogeny of drug disposition.

Authors:  Brian D Chapron; Alenka Chapron; J Steven Leeder
Journal:  Br J Clin Pharmacol       Date:  2021-04-15       Impact factor: 3.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.